Develops antibody-based biotherapeutics targeting immune inhibitory receptors for treating acute myeloid leukemia and other cancers.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Immune-Onc is developing biotherapeutics for cancer. Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute myeloid leukemia (AML) and other cancers.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Immune-Onc Therapeutics Management Team
Investors
CLI Ventures
Fame Mount Limited
Northern Light Venture Capital
Oceanpine Capital
Octagon Investments
Sphera Funds Management
Stanford StartX Fund
Vivo Capital
Immune-Onc Therapeutics Valuations & Financials
View real-time NPM data on Immune-Onc Therapeutics stock including daily Immune-Onc Therapeutics stock price estimates, valuation history, and historical share price information. Access Immune-Onc Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Immune-Onc Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on Immune-Onc Therapeutics? Get in touch to learn more.
Similar Companies
like Immune-Onc Therapeutics
Podium
Enterprise Software
Customer messaging platform enabling companies to connect at critical touch points.
PicsArt
Media & Entertainment
Creative platform providing tools for photo and video editing, graphic design, and digital content creation.
Nostra AI
AI & Machine Learning
Using proprietary Edge Delivery Engine to create fast, engaging online experiences that drive conversions.
Lumeris
Healthcare & Life Sciences
Value-based care managed services operator for health systems and providers.
Jasper
AI & Machine Learning
Automates marketing content creation and workflows with intelligent AI‑driven tools and agents.
Albert
FinTech
Comprehensive financial service that combines advanced technology with human expertise to automate and manage all aspects of personal finances.
Esper
Enterprise Software
Automates device fleets that deploy, monitor, and manage dedicated hardware with DevOps-style orchestration and analytics.
Stability AI
AI & Machine Learning
Open-source AI company focused on developing groundbreaking technologies to benefit humanity.
Kettle
FinTech
Analyzes wildfire risk that uses AI and satellite data to model ignition and spread, helping insurers price and manage property-level exposure.
FAQ
We have answers
Immune-Onc Therapeutics stock does not trade on public stock exchanges. Immune-Onc Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Immune-Onc Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Immune-Onc Therapeutics Stock does not trade on public stock exchanges. In order to sell Immune-Onc Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Immune-Onc Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Immune-Onc Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Immune-Onc Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Immune-Onc Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Immune-Onc Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Immune-Onc Therapeutics is a private company and has not had an IPO. There is currently no Immune-Onc Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Immune-Onc Therapeutics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
